Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CYFRA-21-1 SERUM LEVELS IN WOMEN WITH ADNEXAL MASSES AND INFLAMMATORYDISEASES
Autore:
TEMPFER C; HEFLER L; HEINZL H; LOESCH A; GITSCH G; RUMPOLD H; KAINZ C;
Indirizzi:
UNIV VIENNA,SCH MED,DEPT OBSTET & GYNAECOL,WAHRINGER GURTEL 18-20 A-1090 VIENNA AUSTRIA UNIV VIENNA,SCH MED,DEPT MED COMP SCI A-1090 VIENNA AUSTRIA UNIV VIENNA,SCH MED,DEPT MED LAB DIAGNOST A-1090 VIENNA AUSTRIA
Titolo Testata:
British Journal of Cancer
fascicolo: 8, volume: 78, anno: 1998,
pagine: 1108 - 1112
SICI:
0007-0920(1998)78:8<1108:CSLIWW>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
TISSUE POLYPEPTIDE ANTIGEN; SQUAMOUS-CELL CARCINOMA; NORMAL EPITHELIA; FOLLOW-UP; CANCER; EXPRESSION; CYTOKERATIN-19; MARKER; TPA; PROLIFERATION;
Keywords:
TUMOR MARKER; CYFRA 21-1; ADNEXAL MASSES; OVARIAN CANCER; DIFFERENTIAL DIAGNOSIS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
29
Recensione:
Indirizzi per estratti:
Citazione:
C. Tempfer et al., "CYFRA-21-1 SERUM LEVELS IN WOMEN WITH ADNEXAL MASSES AND INFLAMMATORYDISEASES", British Journal of Cancer, 78(8), 1998, pp. 1108-1112

Abstract

The aim of the present study was to evaluate the clinical usefulness of the cytokeratin marker CYFRA 21-1 as a screening marker for ovariancancer, as a predictive marker in patients with adnexal masses and asa prognostic marker in women suffering from ovarian cancer. In order to determine the specificity of the CYFRA 21-1 test, we have investigated CYFRA 21-1 serum levels in several benign conditions. This retrospective study comprises 37 patients suffering from ovarian cancer FIGO stages la-lll, Sera from patients with benign ovarian cysts, endometriosis, pelvic inflammatory disease, inflammatory bowel disease and liver cirrhosis were evaluated in 90, 10, 38, 10 and 20 cases respectively. With a sensitivity of 41% and a specificity of 95%, CYFRA 21-1 was not suitable as a screening marker for ovarian cancer. Although CYFRA 21-1 was able to discriminate between ovarian cancer and benign adnexaltumours (univariate regression model, P=0.0001), CYFRA 21-1 did not reveal additional information to CA 125 in a multivariate regression analysis (P=0.06), CYFRA 21-1 serum levels were elevated in benign conditions such as liver cirrhosis, but not in endometriosis and inflammatory diseases. In ovarian cancer patients, elevated CYFRA 21-1 serum levels before therapy were associated with a poor overall and disease-free survival (log-rank test, P=0.02 and log-rank test, P=0.005 respectively). CYFRA 21-1, while obviously not suitable for screening or differential diagnosis of adnexal masses, could be useful as an additional prognostic factor in ovarian cancer patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 14/07/20 alle ore 18:29:47